Evidence for behavioral benefits of early dietary supplementation with CoEnzymeQ10 in a slowly progressing mouse model of Huntington's disease

Molecular and Cellular Neuroscience

Volumn 49, Issue 2, 2012, Pages 149-157

  Hickey, Miriam A ^a   Zhu, Chunni ^a   Medvedeva, Vera ^a   Franich, Nicholas R ^a   Levine, Michael S ^a   Chesselet, Marie Françoise ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anti oxidant; Behavior; Huntingtin; Neurodegenerative; Neuropathology; Therapeutic

Indexed keywords

UBIDECARENONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAG REPEAT; COGNITIVE DEFECT; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE COURSE; DISEASE MARKER; DRUG SAFETY; DRUG TOLERABILITY; EMOTIONAL DISORDER; FEMALE; GENE INSERTION; GENE MUTATION; GENETIC TRANSCRIPTION; HOMOZYGOTE; HUNTINGTON CHOREA; IMMUNOHISTOCHEMISTRY; MALE; MOTOR DYSFUNCTION; MOUSE; MUTANT; NERVE DEGENERATION; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; ROTAROD TEST; WILD TYPE;

ANIMALS; BEHAVIOR, ANIMAL; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; UBIQUINONE;

MUS;

EID: 83755174108     PISSN: 10447431     EISSN: 10959327     Source Type: Journal    
DOI: 10.1016/j.mcn.2011.10.007     Document Type: Article

References (60)

1. Andrich J., Saft C., Gerlach M., Schneider B., Arz A., Kuhn W., Muller T. Coenzyme Q10 serum levels in Huntington's disease. J. Neural Transm. Suppl. 2004, 111-116.
2. Arrasate M., Mitra S., Schweitzer E.S., Segal M.R., Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004, 431:805-810.
3. Aylward E.H. Change in MRI striatal volumes as a biomarker in preclinical Huntington's disease. Brain Res. Bull. 2007, 72:152-158.
4. Aylward E.H., Nopoulos P.C., Ross C.A., Langbehn D.R., Pierson R.K., Mills J.A., Johnson H.J., Magnotta V.A., Juhl A.R., Paulsen J.S. Longitudinal change in regional brain volumes in prodromal Huntington disease. J. Neurol. Neurosurg. Psychiatry 2011, 82:405-410.
5. Benn C.L., Fox H., Bates G. Optimisation of region-specific reference gene selection and relative gene expression analysis methods for pre-clinical trials of Huntington's disease. BMC Mol. Neurodegeneration 2008, 3:1-17.
6. Bhagavan H.N., Chopra R.K. Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics. Free Radic. Res. 2006, 40:445-453.
7. Blazquez C., Chiarlone A., Sagredo O., Aguado T., Pazos M.R., Resel E., Palazuelos J., Julien B., Salazar M., Borner C., Benito C., Carrasco C., Diez-Zaera M., Paoletti P., Diaz-Hernandez M., Ruiz C., Sendtner M., Lucas J.J., de Yebenes J.G., Marsicano G., Monory K., Lutz B., Romero J., Alberch J., Gines S., Kraus J., Fernandez-Ruiz J., Galve-Roperh I., Guzman M. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. Brain 2011, 134:119-136.
8. Cattaneo E., Zuccato C., Tartari M. Normal huntingtin function: an alternative approach to Huntington's disease. Nat. Rev. Neurosci. 2005, 6:919-930.
9. Chaturvedi R.K., Beal M.F. Mitochondrial approaches for neuroprotection. Ann. N. Y. Acad. Sci. 2008, 1147:395-412.
10. Cui L., Jeong H., Borovecki F., Parkhurst C.N., Tanese N., Krainc D. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochonrial dysfunction and neurodegeneration. Cell 2006, 127:59-69.
11. Cummings D.M., Andre V.M., Uzgil B.O., Gee S.M., Fisher Y.E., Cepeda C., Levine M.S. Alterations in cortical excitation and inhibition in genetic mouse models of Huntington's disease. J. Neurosci. 2009, 29:10371-10386.
12. Cummings D.M., Cepeda C., Levine M.S. Alterations in striatal synaptic transmission are consistent across genetic mouse models of Huntington's disease. ASN Neuro 2010, 2:e00036.
13. Fariello R.G., Ghilardi O., Peschechera A., Ramacci M.T., Angelucci L. Regional distribution of ubiquinones and tocopherols in the mouse brain: lowest content of ubiquinols in the substantia nigra. Neuropharmacology 1988, 27:1077-1080.
14. Feigin A., Kieburtz K., Como P., Hickey C., Claude K., Abwender D., Zimmerman C., Steinberg K., Shoulson I. Assessment of coenzyme Q10 tolerability in Huntington's disease. Mov. Disord. 1996, 11:321-323.
15. Ferrante R.J., Andreassen O.A., Dedeoglu A., Ferrante K.L., Jenkins B.G., Hersch S.M., Beal M.F. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J. Neurosci. 2002, 22:1592-1599.
16. Ferrante K.L., Shefner J., Zhang H., Betensky R., O'Brien M., Yu H., Fantasia M., Taft J., Beal M.F., Traynor B., Newhall K., Donofrio P., Caress J., Ashburn C., Freiberg B., O'Neill C., Paladenech C., Walker T., Pestronk A., Abrams B., Florence J., Renna R., Schierbecker J., Malkus B., Cudkowicz M. Tolerance of high-dose (3,000mg/day) coenzyme Q10 in ALS. Neurology 2005, 65:1834-1836.
17. Glass M., Dragunow M., Faull R.L. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 2000, 97:505-519.
18. Hickey M.A., Gallant K., Gross G.G., Levine M.S., Chesselet M.F. Early behavioral deficits in R6/2 mice suitable for use in preclinical drug testing. Neurobiol. Dis. 2005, 20:1-11.
19. Hickey M.A., Kosmalska A., Enayati J., Cohen R., Zeitlin S., Levine M.S., Chesselet M.F. Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice. Neuroscience 2008, 157:280-295.
20. Hickey M.A., Franich N.R., Medvedeva V., Chesselet M.F. Mouse models of mental illness and neurological disease. The Mouse Nervous System 2011, 32:752-765. Elsevier, London. C. Watson, G. Paxinos, L. Puelles (Eds.).
21. Hockly E., Cordery P.M., Woodman B., Mahal A., van Dellen A., Blakemore C., Lewis C.M., Hannan A.J., Bates G.P. Environmental enrichment slows disease progression in R6/2 Huntington's disease mice. Ann. Neurol. 2002, 51:235-242.
22. Hockly E., Richon V.M., Woodman B., Smith D.L., Zhou X., Rosa E., Sathasivam K., Ghazi-Noori S., Mahal A., Lowden P.A., Steffan J.S., Marsh J.L., Thompson L.M., Lewis C.M., Marks P.A., Bates G.P. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:2041-2046.
23. Hockly E., Tse J., Barker A.L., Moolman D.L., Beunard J.L., Revington A.P., Holt K., Sunshine S., Moffitt H., Sathasivam K., Woodman B., Wanker E.E., Lowden P.A., Bates G.P. Evaluation of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for Huntington's disease. Neurobiol. Dis. 2006, 21:228-236.
24. Kamzalov S., Sumien N., Forster M.J., Sohal R.S. Coenzyme Q intake elevates the mitochondrial and tissue levels of Coenzyme Q and alpha-tocopherol in young mice. J. Nutr. 2003, 133:3175-3180.
25. Kim J., Moody J.P., Edgerly C.K., Bordiuk O.L., Cormier K., Smith K., Beal M.F., Ferrante R.J. Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease. Hum. Mol. Genet. 2010, 19:3919-3935.
26. Klapstein G.J., Fisher R.S., Zanjani H., Cepeda C., Jokel E.S., Chesselet M.F., Levine M.S. Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. J. Neurophysiol. 2001, 86:2667-2677.
27. Koroshetz W.J., Jenkins B.G., Rosen B.R., Beal M.F. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann. Neurol. 1997, 41:160-165.
28. Kwong L.K., Kamzalov S., Rebrin I., Bayne A.C., Jana C.K., Morris P., Forster M.J., Sohal R.S. Effects of coenzyme Q(10) administration on its tissue concentrations, mitochondrial oxidant generation, and oxidative stress in the rat. Free Radic. Biol. Med. 2002, 33:627-638.
29. Lee J.M., Ivanova E.V., Seong I.S., Cashorali T., Kohane I., Gusella J.F., MacDonald M.E. Unbiased gene expression analysis implicates the huntingtin polyglutamine tract in extra-mitochondrial energy metabolism. PLoS Genet. 2007, 3:e135.
30. Matthews R.T., Yang L., Browne S., Baik M., Beal M.F. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc. Natl. Acad. Sci. 1998, 95:8892-8897.
31. Menalled L., Zanjani H., MacKenzie L., Koppel A., Carpenter E., Zeitlin S., Chesselet M.-F. Decrease in striatal enkephalin mRNA in mouse models of Huntington's disease. Exp. Neurol. 2000, 162:328-342.
32. Menalled L.B., Sison J.D., Dragatsis I., Zeitlin S., Chesselet M.F. Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats. J. Comp. Neurol. 2003, 465:11-26.
33. Menalled L.B., Patry M., Ragland N., Lowden P.A., Goodman J., Minnich J., Zahasky B., Park L., Leeds J., Howland D., Signer E., Tobin A.J., Brunner D. Comprehensive behavioral testing in the R6/2 mouse model of Huntington's disease shows no benefit from CoQ10 or minocycline. PLoS One 2010, 5:e9793.
34. Miller J., Arrasate M., Shaby B.A., Mitra S., Masliah E., Finkbeiner S. Quantitative relationships between huntingtin levels, polyglutamine length, inclusion body formation, and neuronal death provide novel insight into Huntington's disease molecular pathogenesis. J. Neurosci. 2010, 30:10541-10550.
35. Okamoto S., Pouladi M.A., Talantova M., Yao D., Xia P., Ehrnhoefer D.E., Zaidi R., Clemente A., Kaul M., Graham R.K., Zhang D., Vincent Chen H.S., Tong G., Hayden M.R., Lipton S.A. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat. Med. 2009, 15:1407-1413.
36. Paxinos G., Franklin K.B.J. The Mouse Brain in Stereotaxic Coordinates 2001, Academic Press, Florida. 2nd ed.
37. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001, 29:e45.
38. Phan J., Hickey M.A., Zhang P., Chesselet M.F., Reue K. Adipose tissue dysfunction tracks disease progression in two Huntington's disease mouse models. Hum. Mol. Genet. 2009, 18:1006-1016.
39. Ribchester R.R., Thomson D., Wood N.I., Hinks T., Gillingwater T.H., Wishart T.M., Court F.A., Morton A.J. Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington's disease mutation. Eur. J. Neurosci. 2004, 20:3092-3114.
40. Sathasivam K., Hobbs C., Turmaine M., Mangiarini L., Mahal A., Bertaux F., Wanker E.E., Doherty P., Davies S.W., Bates G.P. Formation of polyglutamine inclusions in non-CNS tissue. Hum. Mol. Genet. 1999, 8:813-822.
41. Saudou F., Finkbeiner S., Devys D., Greenberg M.E. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 1998, 95:55-66.
42. Schilling G., Coonfield M.L., Ross C.A., Borchelt D.R. Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model. Neurosci. Lett. 2001, 315:149-153.
43. Schilling G., Savonenko A.V., Coonfield M.L., Morton J.L., Vorovich E., Gale A., Neslon C., Chan N., Eaton M., Fromholt D., Ross C.A., Borchelt D.R. Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice. Exp. Neurol. 2004, 187:137-149.
44. Shults C.W., Beal M.F., Fontaine D., Nakano K., Haas R.H. Absorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonian patients. Neurology 1998, 50:793-795.
45. Shults C.W., Flint Beal M., Song D., Fontaine D. Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease. Exp. Neurol. 2004, 188:491-494.
46. Simmons D.A., Rex C.S., Palmer L., Pandyarajan V., Fedulov V., Gall C.M., Lynch G. Up-regulating BDNF with an ampakine rescues synaptic plasticity and memory in Huntington's disease knockin mice. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:4906-4911.
47. Smith K.M., Matson S., Matson W.R., Cormier K., Del Signore S.J., Hagerty S.W., Stack E.C., Ryu H., Ferrante R.J. Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice. Biochim. Biophys. Acta 2006, 1762:616-626.
48. Stack E.C., Smith K.M., Ryu H., Cormier K., Chen M., Hagerty S.W., Del Signore S.J., Cudkowicz M.E., Friedlander R.M., Ferrante R.J. Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice. Biochim. Biophys. Acta 2006, 1762:373-380.
49. Stout J.C., Paulsen J.S., Queller S., Solomon A.C., Whitlock K.B., Campbell J.C., Carlozzi N., Duff K., Beglinger L.J., Langbehn D.R., Johnson S.A., Biglan K.M., Aylward E.H. Neurocognitive signs in prodromal Huntington disease. Neuropsychology 2011, 25:1-14.
50. Strand A.D., Aragaki A.K., Shaw D., Bird T., Holton J., Turner C., Tapscott S.J., Tabrizi S.J., Schapira A.H., Kooperberg C., Olson J.M. Gene expression in Huntington's disease skeletal muscle: a potential biomarker. Hum. Mol. Genet. 2005, 14:1863-1876.
51. The Huntington Study Group A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 2001, 57:397-404.
52. The Huntington Study Group Pre2CARE Investigators Safety and tolerability of high-dose coenzyme Q10 in Huntington's disease and healthy subjects. Mov. Disord. 2010, 25:1924-1928.
53. The Huntington's Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72:971-983.
54. Turner C., Cooper J.M., Schapira A.H. Clinical correlates of mitochondrial function in Huntington's disease muscle. Mov. Disord. 2007, 22:1715-1721.
55. Underwood B.R., Imarisio S., Fleming A., Rose C., Krishna G., Heard P., Quick M., Korolchuk V.I., Renna M., Sarkar S., Garcia-Arencibia M., O'Kane C.J., Murphy M.P., Rubinsztein D.C. Antioxidants can inhibit basal autophagy and enhance neurodegeneration in models of polyglutamine disease. Hum. Mol. Genet. 2010, 19:3413-3429.
56. van der Burg J.M., Bacos K., Wood N.I., Lindqvist A., Wierup N., Woodman B., Wamsteeker J.I., Smith R., Deierborg T., Kuhar M.J., Bates G.P., Mulder H., Erlanson-Albertsson C., Morton A.J., Brundin P., Petersen A., Bjorkqvist M. Increased metabolism in the R6/2 mouse model of Huntington's disease. Neurobiol. Dis. 2008, 29:41-51.
57. Weydt P., Pineda V.V., Torrence A.E., Libby R.T., Satterfield T.F., Lazarowski E.R., Gilbert M.L., Morton G.J., Bammler T.K., Strand A.D., Cui L., Beyer R.P., Easley C.N., Smith A.C., Krainc D., Luquet S., Sweet I.R., Schwartz M.W., La Spada A.R. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. Cell Metab. 2006, 4:349-362.
58. Yang L., Calingasan N.Y., Wille E.J., Cormier K., Smith K., Ferrante R.J., Beal M.F. Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases. J. Neurochem. 2009, 109:1427-1439.
59. Zhang Y., Aberg F., Appelkvist E.L., Dallner G., Ernster L. Uptake of dietary coenzyme Q supplement is limited in rats. J. Nutr. 1995, 125:446-453.
60. Zhang Y., Turunen M., Appelkvist E.L. Restricted uptake of dietary coenzyme Q is in contrast to the unrestricted uptake of alpha-tocopherol into rat organs and cells. J. Nutr. 1996, 126:2089-2097.